EASi-PROTKT
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, arterial hypertension and established cardiovascular disease
- Stage
- inclusie
- Medicine
- Vicadrostat + Enpagliflozin
- Population
- ASCVD
- Phase
- III
- First Patient In
- 1 January 2026
- Last Patient In
- 31 December 2026
- Last Patient Last Visit
- 12 October 2029
Inclusion period, 336 days remaining
National Lead
prof. dr. F.M.A.C. Martens
Cardioloog
Study Director
